Park Ha Biological Technology Co., Ltd. Announces Closing of a US$2.45 Million Public Offering

Rhea-AI Summary

Park Ha Biological Technology (NASDAQ: BYAH) closed a best-efforts follow-on offering of 21,875,000 units at US$0.112 per unit on January 28, 2026, generating approximately US$2.45 million in gross proceeds.

Each unit includes one Class A ordinary share and one warrant exercisable at US$0.112 through the one-year anniversary, with an alternative cashless exercise allowing up to nine shares. Net proceeds are intended to fund expansion of directly operated stores in China.

Positive

• Gross proceeds of approximately US$2.45 million
• Proceeds earmarked for expansion of directly operated stores in China

Negative

• 21,875,000 units issued, creating immediate share and warrant dilution
• Each warrant exercisable at US$0.112 for one share or cashless up to nine shares within one year

News Market Reaction – BYAH

-23.60% 243.7x vol

19 alerts

-23.60% News Effect

+56.0% Peak Tracked

-28.6% Trough Tracked

-$1M Valuation Impact

$4M Market Cap

243.7x Rel. Volume

On the day this news was published, BYAH declined 23.60%, reflecting a significant negative market reaction. Argus tracked a peak move of +56.0% during that session. Argus tracked a trough of -28.6% from its starting point during tracking. Our momentum scanner triggered 19 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $1M from the company's valuation, bringing the market cap to $4M at that time. Trading volume was exceptionally heavy at 243.7x the daily average, suggesting significant selling pressure.

Data tracked by StockTitan Argus on the day of publication.

Wuxi, China, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Park Ha Biological Technology Co., Ltd. (NASDAQ: BYAH) (the “Company”) today announced the closing of a best-efforts follow-on public offering of 21,875,000 units (each a “Unit”) at an offering price of US$0.112 per Unit.

Each Unit consists of one Class A ordinary share of the Company, par value US$0.00002 per share (each, a “Class A Ordinary Share”) and one warrant to purchase one Class A Ordinary Share, or up to nine Class A Ordinary Shares pursuant to the alternative cashless exercise mechanism described therein (each, a “Warrant”). Each Warrant has an exercise price of US$0.112 per Class A Ordinary Share and is exercisable beginning on the issuance date and ending on the one-year anniversary of the issuance date.

Gross proceeds to the Company, before deducting placement agent’s commissions and other offering expenses, were approximately US$2.45 million. The Company intends to use the net proceeds of the Offering for the expansion of directly operated stores in China, and the specific allocation of net proceeds to each market will be based on market conditions.

D. Boral Capital LLC acted as the Sole Placement Agent for the Offering.

A registration statement on Form F-1, as amended (File No. 333- 290410), relating to the Offering was filed with the U.S. Securities and Exchange Commission (the “SEC”) and was declared effective by the SEC on January 26, 2026. The Offering was made only by means of a prospectus, forming part of the effective registration statement. A copy of the final prospectus relating to the Offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the prospectus may be obtained from D. Boral Capital LLC at info@dboralcapital.com, or by calling +1 (212) 970-5150.

About Park Ha Biological Technology Co., Ltd.

Established in 2016, Park Ha Biological Technology Co., Ltd. is primarily engaged in developing its private skincare label, direct skincare products sales and franchise alliances promotions under the proprietary brand “Park Ha”, with a commitment to providing cost-effective solutions to skin problems and improving the confidence of women in need of skin treatment. As of April 30, 2025, the Company has three directly operated stores and 39 franchisees, of which 38 and one operate under the store name “Park Ha” and “Geni” respectively, in China. As part of its value-added service for the products, the Company offers “light beauty experience”, a quick complimentary after-sales beauty service performed in the directly-operated stores and franchise stores. For more information, please visit the Company’s website: http://ir.parkha.cn/.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this announcement. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For more information, please contact:

D. Boral Capital LLC
590 Madison Avenue, 39th Floor
New York, NY 10022
Main Phone: +1 (212) 970-5150
www.dboralcapital.com
info@dboralcapital.com

Park Ha Biological Technology Co., Ltd.
901, Building C
Phase 2, Wuxi International Life Science Innovation Campus
196 Jinghui East Road
Xinwu District, Wuxi, Jiangsu Province
People’s Republic of China 214000
http://ir.parkha.cn/
ir_parkha@163.com

FAQ

How many units did Park Ha Biological (BYAH) sell in the January 28, 2026 offering?

Park Ha sold 21,875,000 units in the offering. According to the company, each unit included one Class A ordinary share and one warrant exercisable for a share or cashless up to nine shares.

What price per unit and total gross proceeds did BYAH raise in the offering?

The offering price was US$0.112 per unit, raising about US$2.45 million gross. According to the company, this is before placement agent commissions and offering expenses.

What are the warrant terms in Park Ha Biological's (BYAH) follow-on offering?

Each warrant has an exercise price of US$0.112 and is exercisable immediately until the one-year anniversary. According to the company, warrants include an alternative cashless exercise enabling up to nine shares.

How does BYAH plan to use the net proceeds from the January 2026 offering?

Net proceeds will fund the expansion of directly operated stores in China. According to the company, allocation to each market will be based on prevailing market conditions.

Who acted as placement agent and was the offering registered with the SEC for BYAH?

D. Boral Capital LLC acted as the sole placement agent. According to the company, the Form F-1 registration (File No. 333-290410) was declared effective by the SEC on January 26, 2026.

When do the BYAH warrants expire and can they be exercised cashlessly?

Warrants expire one year after issuance and are exercisable from issuance date. According to the company, warrants permit an alternative cashless exercise mechanism converting to up to nine Class A shares.